This was a double-blind, placebo-controlled, randomized trial performed in 30 countries, and 780 patients were randomly assigned to the study treatment, which was the largest study of HER2-targeted therapy for gastric cancer to date. The gene discussed is ERBB2; the disease is gastric cancer.